An experimental treatment for Alzheimer's failed again in a widely anticipated study, disappointing many who had hoped drugmaker Eli Lilly had finally found a way to slow the progression of the mind-robbing disease. The drug did not work better than a placebo treatment in a study of more than...
Final-stage results dash hopes that solanezumab, an injectable antibody, would provide treatment breakthrough A drug that was seen as a strong contender to slow the progression of Alzheimer’s disease has failed to deliver in the final...Show More Summary
Alzheimer's disease is a progressive disease that destroys memory and other important mental functions. Many people who have relatives with this disease worry that it may run in the family. Does having a family member with Alzheimer's disease increase your risk of developing it? In this Mayo Clinic Minute, reporter Vivien Williams talks to Dr. […]
Dementia is now the commonest cause of death in England and Wales, and although Alzheimer’s was first identified more than a century ago, effective treatments have proved elusive. But progress may now be in sight Related: Sea Hero Quest: the mobile phone game helping fight dementia Most of us forget names, dates or places from time to time. Show More Summary
When Lilly releases the results of Expedition 3, the Alzheimer's field may once again experience how progress in treating this disease is conjoined to vexing challenges. How do we make sense of the treatment’s benefit? This question sustains a decades old search for a coherent language of benefit.
This recent popular science article looks at the state of research into Alzheimer's disease and other forms of dementia. There is, so far, little tangible progress in the clinic resulting from the past twenty years of efforts in the laboratory. Show More Summary
Alzheimer's disease is a progressive loss of memory and cognition, for which there is no cure. Although genetic studies initially suggested a primary role for amyloid-in Alzheimer's disease, treatment strategies targeted at reducing amyloid-have failed to reverse cognitive symptoms. These clinical findings suggest that cognitive
(Cornell University) Researchers provide unprecedented evidence that basal forebrain pathology precedes and predicts both entorhinal pathology and memory impairment in people with Alzheimer's disease.
ROCHESTER, Minn. – Dementia with Lewy bodies is a progressive disease that causes hallucinations, decline in mental abilities, rigid muscles, slow movement and tremors. With symptoms similar to Alzheimer’s disease and Parkinson’s disease, a correct diagnosis can be difficult. A new study published today in the online issue of Neurology, a medical journal of the […]
Alzheimer’s disease risk may be lowered by treating high blood pressure, high cholesterol, and diabetes. The study followed 837 people with mild cognitive impairment which can progress into Alzheimer’s disease. Of the group, 414 participants...Show More Summary
(Massachusetts General Hospital) Use of a novel approach to analyzing brain structure that focuses on the shape rather than the size of particular features may allow identification of individuals in early presymptomatic stages of Alzheimer's disease.
There has been a fair amount of news regarding the SkQ class of mitochondrially targeted antioxidant this past year, most likely because clinical development in Europe is moving ahead. Having one or more for-profit entities involved,...Show More Summary
Mild cognitive impairment (MCI) patients with anxiety face faster Alzheimer’s disease progression. The risk of Alzheimer’s disease in mild cognitive impairment patients with mild, moderate, and severe anxiety was found to increase by...Show More Summary
Recent studies have shown that the quality and atmosphere of buildings can slow the progression of Alzheimer's disease and dementia and promote good health. The therapeutic features and overall design of the innovative new Alzheimer Village in France was created with this idea in mind. Show More Summary
For decades, people have been hoping for the magic bullet that will prevent, cure, or even slow the progression of Alzheimer’s Disease or other dementias. Yet, despite small hints of progress-- and billions of dollars in research--there is no drug, and no app or game, that can successfully treat these [...]
FASTER, PLEASE: Test Of Experimental Alzheimer’s Drug Finds Progress Against Brain Plaques.
Multivariate analysis of cognitive tests in Alzheimer's disease identifies five distinct groups of Alzheimer's disease patients, and suggests that multivitamins might slow progression only in certain groups.
Inflammation in the brain contributes to the progression of Alzheimer's disease. This has been known for some time, but there has been surprisingly little progress in building anti-inflammatory treatments. Some years ago, one approach using existing anti-inflammatory drugs failed in clinical trials, for example. Show More Summary
The way in which Alzheimer's brain changes progress is linked to poor control of protein in specific areas of the brain. New research maps these changes.
Researchers have identified a protein essential for building memories that appears to predict the progression of memory loss and brain atrophy in Alzheimer's patients. Their findings suggest there is a link between brain activity and the presence of this protein.